Cost considerations in the evaluation of new therapies for gram-positive bacteria

International Journal of Antimicrobial Agents

Volumn 13, Issue 2, 1999, Pages 71-78

  Nathwani, Dilip ^a   Malek, Mo ^b  

^a NHS TAYSIDE   (United Kingdom)

^b UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

Antibiotic resistance; Formulary; Gram positive infections; Linezolid; Pharmacoeconomics

Indexed keywords

LINEZOLID;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; COST BENEFIT ANALYSIS; DRUG FORMULARY; GRAM POSITIVE BACTERIUM; HEALTH CARE POLICY; HUMAN; PHARMACOECONOMICS; PRIORITY JOURNAL; REVIEW;

EID: 0033213514     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(99)00102-8     Document Type: Note

References (56)

1. Goldman DA, Huskins WC. Control of nosocomial antibiotic resistant bacteria: A strategic priority for hospitals worldwide. Clin Infect Dis 1997;24(1):S139-45.
2. McGowan JE Jr. Antimicrobial resistance in hospital organisms and its relation to antibiotic use. Rev Infect Dis 1983;16:75-81.
3. Gold HS, Moellering RC Jr. Antimicrobial drug-resistance. N Engl J Med 1996;335:1445-53.
4. Waldvogel FA. New resistance in Staphylococcus aureus. N Engl J Med 1999;340:556-7.
5. Moellering RC Jr. Problems with antimicrobial resistance in gram-positive cocci. Clin Infect Dis 1998;26:1177-8.
6. Moellering RC Jr. Vancomycin-resistant enterococci. Clin Infect Dis 1998;26:1196-9.
7. Hiramatsu K, HAnaki H, Yabatu K, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997;40:135-6.
8. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999;340:493-501.
9. Spencer RC. Clinical impact and costs of Clostridium difficle-associated disease. J Antimicrob Chemother 1998;41C:5-12.
10. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infection. A risk factor for hospital mortality among critically ill patients. Chest 1999;115:462-74.
11. Pallares R, Dick R, Wenzel RP, Adams JR, Nettleman MD. Trends in antimicrobial utilization at a tertiary teaching hospital during a 15 year period. Infect Control Hosp Epidemiol 1993;14:376-82.
12. Dunagan WC, Woodward RS, Medoff G, et al. Antimicrobial misuse in patients with positive blood cultures. Am J Med 1989;87:253-9.
13. Coast J, Smith RD, Millar MR. Superbugs: Should antimicrobial resistance be included as a cost in economic evaluation? Health Econ 1996;5:217-26.
14. Mosdell DM, Morris DM, Voltura A, et al. Antibiotic treatment of surgical peritonitis. Ann Surg 1991;214:543-9.
15. Shulkin DJ, Kinosian B, Glick H, et al. The economic impact of infections: An analysis of hospital costs and charges in surgical patients with cancer. Arch Surg 1993;128:449-52.
16. Pallares R, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995;333:474-80.
17. Select Committee on Science and Technology. Resistance to antibiotics. House of Lords: Session 1997-1998, 7th Report.
18. Bax RP, Anderson R, Crew J, et al. Antibiotic resistance - What can we do? Nat Med 1998;4(5):1-2.
19. Davey PG, Malek M. Defining criteria for the pharmaco-economic evaluation of new oral cephalosporins. PharmacoeconomIcs 1994;5(2):11-9.
20. Malek M. Current principles and application of pharmacoeconomics. Pharmacoeconomics 1996;9(1):1-8.
21. Malek M. Pharmacoeconomics: An introduction. Pharm J 1996;256:759-61.
22. Malek M, Davey PG, McDonald T, Dodd T. Principles and practice of pharmacoeconomics. In: Speight TM, Avery's Drug Treatment, 4th Edition, Ch 10. Adis International Limited, 1997. p. 393-422. Published in: Auckland, NZ.
23. Parker S, Davey P. Pharmacoeconomics of intravenous drug administration. Pharmacoeconomics 1992; 1:103-15.
24. McCue JD, Hansen C, Gal P. Hospital charges for antibiotics. Rev Infect Dis 1985;7(5):643-5.
25. Malek M, Lynch W, Wells N, et al. A comparison of the costs of ceftazidime therapy and gentamicin combinations in three UK hospitals. J Antimicrob Chemother 1992;29:207-17.
26. Griffin JP. The need for pharmacoeconomic evaluations in the NHS. Pharmacoeconomics 1998;14(3):241-50.
27. Moellering RC Jr. A novel antimicrobial agent joins the battle against resistant bacteria. Ann Intern Med 1999;130:155-157.
28. Linden PK. Clinical implications of nosocomial gram-positive bacteraemia and superimposed antimicrobial resistance. Am J Med 1998;104(5A):24S-33S.
29. Fagon JY, Maillet TM, Novara A. Hospital-acquired pneumonia: Methicillin resistance and intensive care unit admission. Am J Med 1998;104(5a):17S-23S.
30. Jones RN, Barrett MS, Erwin ME. In vitro activity and spectrum of LY333328, a novel glycopeptide derivative. Antimicrob Agents Chemother 1997;39:488-93.
31. Weinstein MJ, Luedemann GM, Oden EM, Wagman GH. Everninomicin, a new antibiotic complex from Micromonospora carbonacea. Antimicrob Agents Chemother. Bethesda MD, American Society of Microbiology, 1965. p. 24-32.
32. Willey BM, Sachse L, Mustachi B, et al. Comparative in vitro activities of a new oligosaccharide: Everninomicin (SH27988) against clinical enterococci. In: Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15-18: New Orleans.
33. Dowzicky M, Nadler HL, Feger C, et al. Evaluation of in vitro activity of quinupristin/dalfopristin and comparator antimicrobial agents against worldwide clinical trial and other laboratory isolates. Am J Med 1998;104(5A):34S-42S.
34. Linden PK, Pasculle AW, McDevitt D, Kramer DJ. Effect of quinupristin/dalfopristin on the outcome of vancomycin-resistant Enterococcus faecium bacteraemia: Comparison with a control cohort. J Antimicrob Chemother 1997;39:S145-S51.
35. Cammarata SK, Hafkin B, Demke DM, Eckert DH. Efficacy of linezolid in skin & soft tissue infections. In: Abstract of the 9th European Congress of Clinical Microbiology and Infectious Diseases. Berlin, Germany, March 21-24, 1999. Abstract No. P181.
36. Shinabarger DL, Marotti KR, Murray RW, et al. Mechanism of action of oxazolidinones: Effects of linezolid and eperezolid on translation reactions. Antimicrob Agents Chemother 1998;42:947-50.
37. Mossialos E, Kanavanos P, Abel-Smith B. Will managed care work in Europe? Pharmacoeconomics 1997;11(4):297-305.
38. Grimshaw JM, Russell IT. Achieving health gain through clinical guidelines. 1. Developing scientifically valid guidelines. Qual Health Care 1993;2:243-8.
39. Goldmann DA, Weinstein RA, Wenzel RP, Tablan OC, Duma RJ, Gaynes RP et al. Strategies to prevent and control the emergence and spread of antimicrobial resistant microorganisms in hospitals. J Am Med Assoc 1996;275:234-240.
40. Hospital antibiotic control measures in the UK. Working party of the British society for antimicrobial chemotherapy. Journal of Antimicrobial Chemotherapy 1994;34:21-42.
41. Nathwani D, Davey P. Strategies to rationalize sepsis management - A review of 4 years' experience in Dundee. J Infect (Suppl) 1998;1:10-7.
42. Bochner F, Martin ED, Burgess N, et al. Drug rationing in a teaching hospital: A method to assign priorities. Br Med J 1994;308:901-5.
43. Lipsey RJ. Institutional formularies: The relevance of pharmacoeconomic analysis to formulary decisions. Pharmacoeconomics 1992;1(4):265-81.
44. Johnson JA, Friesen E. Reassessing the relevance of pharmacoeconomic analyses in formulary decisions. Pharmacoeconomics 1998;13:479-85.
45. British medical journal economic evaluation working party: Guidelines for authors and peer reviewers of economic submissions to BMJ. Br Med J 1996; 313: 275-83.
46. Palteil AD, Neumann PJ. Why training is the key to successful guideline implementation. Pharmacoeconomics 1997;12(3):297- 302.
47. Davey PG, Malek MM. Defining criteria for the pharmaco-economic evaluation of new oral cephalosporins. Pharmacoeconomics 1994;5(2):11-9.
48. Gugliemo BJ, Brooks GF. Antimicrobial therapy. Cost-benefit considerations. Drugs 1989;38(4):473-80.
49. Byford S, Palmer S. Common errors and controversies in pharmacoeconomic analyses. Pharmacoeconomics 1998;13(6):659- 66.
50. Coyle D, Lee KM. The problem of protocol driven costs in pharmacoeconomic analysis. Pharmacoeconomics 1998;14(4):357-63.
51. Nathwani D, Conlon C, on behalf of the OHPAT Working Party. Outpatient and home parenteral antibiotic therapy in the UK: A consensus statement by a working party. Clin Microb Infect 1998;4:537-551.
52. Ruta DA, Garratt AM, Leng M, et al. A new approach to the measurement of quality of life. Med Care 1994;32(11):1109-26.
53. Gladden H. Evaluating the cost-effectiveness of treatment with third generation cephalosporins. Diagn Microbiol Infect Dis 1992;15:99-105.
54. Jewesson P. Cost-effectiveness and value of an IV switch. Pharmacoeconomics 1994;5(2):20-6.
55. Wright SW, Wrenn KD. Appropriateness of vancomycin use in the emergency department. Ann Emerg Med 1998;32(5):531-7.
56. Spencer CM, Bryson HM. Teicoplanin: A pharmacoeconomic evaluation of its use in the treatment of gram-positive infections. Pharmacoeconomics 1995;7(4):357-74.